Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy

摘要: Background Several cytokines including transforming growth factor (TGF)-β1 have been suggested to be involved in the pathogenesis of fibrosis chronic hepatitis C. We examined changes TGF-β1 serum levels and their predictive value patients with C under antiviral therapy. Methods included 84 who were treated pegylated interferon-α ribavirin between 2008 2009. Treatment was given for 24-48 weeks depending on HCV genotype. Serum measured by an ELISA assay at baseline, end therapy (EOT), 6 months after EOT. Liver evaluated transient elastography. Results Of patients, 76.2% achieved sustained virological response (SVR), 8.3% responded EOT but relapsed during post-therapy follow up (RR) 15.5% had no (NR). In all mean 16,980 pg/mL baseline decreased signifi cantly (12,041 pg/mL) post-treatment (13,254 (P≤0.001). particular, from six SVR numerically not RR or NR. associated severity liver stiffness estimated Conclusion Our data show that decrease remain mostly achieve combination treatment. Keywords TGF-β1, HCV, elastography, treatment, Ann Gastroenterol 2016; 29 (1): 79-84